45 reports

Respiratory disorders such as asthma, interstitial lung disease (ILD), tuberculosis (TB), chronic obstructive pulmonary disease (COPD), and pneumonia are on the rise.

  • Respiratory Disease
  • Boston Scientific Corporation
  • Broncus Medical Inc.
  • Medtronic, Inc.
  • Olympus Corporation
  • CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  • RESPIRATORY CARE DEVICES GLOBAL MARKET , BY APPLICATION (2014-2022) ($MN)

TUBERCULOSIS (TB) INCIDENCE IS MUCH HIGHER IN BIG CITIES.

  • Respiratory Disease
  • World
  • Market Size
  • Medtronic, Inc.
  • ResMed Inc.
  • IMPORTANT CAUSES OF DEATH AND DISABILITY DURING THE PAST TWO DECADES SINCE 2011
  • Respiratory Disease
  • World
  • Market Size
  • Astra Group
  • Becton Property Group
  • ANTHONISEN NR (2005). LUNG HEALTH STUDY RESEARCH GROUP. ANN INTERN MED; 142(4): 233-239
  • PELAIA G, ET AL. (2012). THE POTENTIAL OF BIOLOGICS FOR THE TREATMENT OF ASTHMA. NATURE DRUG DISCOVERY; 11: 958-972

THE PULMONOLOGIST MAY ALSO ASK FOR A SKIN TEST TO DETERMINE THE PRESENCE OF TUBERCULOSIS.

  • Respiratory Disease
  • World
  • Market Size
  • Astellas Pharma Inc.
  • AstraZeneca PLC

Produces diagnostic devices for respiratory viruses, tuberculosis, hepatitis, and cervical cancer.

  • Respiratory Disease
  • World
  • Alere Inc.
  • CareFusion Corporation
  • Nihon Kohden Corporation
  • ASTHMA
  • GROWING INCIDENCE OF CHRONIC RESPIRATORY DISEASES

This device is mainly used for people with pulmonary tuberculosis, which is a highly infectious disease.

  • Respiratory Disease
  • World
  • Market Size
  • CareFusion Corporation
  • Teleflex Incorporated

CHEST X-RAY MAY SHOW ENLARGED LUNGS, IRREGULAR AIR POCKETS (BULLAE), OR A FLATTENED DIAPHRAGM, AND CAN HELP RULE OUT OTHER DISEASES, SUCH AS LUNG CANCER AND TUBERCULOSIS.

  • Respiratory Disease
  • Demand
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Sunovion Pharmaceuticals Inc.

The pulmonologist may also ask for a skin test to determine the presence of tuberculosis.

  • Respiratory Disease
  • World
  • Market Size
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • SOURCES NOT USED FOR COPD ANALYSES IN THE US, JAPAN, FIVE MAJOR EU MARKETS, AND CHINA
  • SOURCES NOT USED FOR COPD ANALYSES IN THE US, JAPAN, FIVE MAJOR EU MARKETS, AND CHINA

Furthermore, asthma and tuberculosis cases were excluded.

  • Respiratory Disease
  • Asia
  • Europe
  • Japan
  • World

tuberculosis Respiratory distress syndrome December 2012 March 2012 COPD July 2012 Forest Laboratories Novartis COPD July 2011 DRUG COMPANY INDICATION APPROVED DATE ADCIRCA (TADALAFIL) Eli Lilly DALIRESP (ROFLUMILAST) CAYSTON (AZTREONAM FOR INHALATION SOLUTION) DULERA (MOMETASONE FUROATE +

  • Respiratory Disease
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • 9.2.6 JAPAN

Egyptian Journal of Chest Diseases and Tuberculosis; ##: ##-## Reed CE (1999).

  • Respiratory Disease
  • World
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Novartis AG

TUBERCULOSIS AND RESPIRATORY DISEASES GLAXOSMITHKLINE PLC ## MAR 2009 ## MAR 2010 ## ## ## ## BETA ## ADRENERGIC RECEPTOR (BETA ## ADRENORECEPTOR OR ADRB##) AGONIST; GLUCOCORTICOID RECEPTOR (GR OR NUCLEAR RECEPTOR SUBFAMILY ## GROUP C MEMBER ## OR NR##C##) AGONIST BETA ## ADRENERGIC RECEPTOR (BETA

  • Hospital
  • Respiratory Disease
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc

Placebo, in Patients with Moderate-to-severe COPD with Destroyed Lung by Tuberculosis Indacaterol Effectiveness in COPD Patients with Tuberculosis History (INFINITY) GDCT## NCT##, CQAB##BKR## Respiratory Chronic Obstructive Pulmonary Disease (COPD),

  • Respiratory Disease
  • World
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • 9.3 References

Egyptian Journal of Chest Diseases and Tuberculosis; ##: ##-## Reiss TF, et al. (1998).

  • Respiratory Disease
  • Asia
  • World
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Clinical Trial profile. 1747 Trial Title

Tuberculosis and Lung Disease ## Feb 2012 ## ## ## Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Collaborator(s) Estimated Start Date # of Subjects Planned # of Location(s) # of Investigator(s) Clinical Tria

  • Respiratory Disease
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • 7.3 References

Egyptian Journal of Chest Diseases and Tuberculosis; ##: ##-## Reed CE (1999).

  • Respiratory Disease
  • World
  • Market Size
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET SIZE, BY DISEASE, 2014-2021 (USD MILLION)
  • ROW: RESPIRATORY DIAGNOSTICS MARKET SIZE, BY DISEASE, 2014-2021 (USD MILLION)

RESPIRATORY DIAGNOSTICS MARKET SIZE FOR TUBERCULOSIS, BY REGION, 2014-2021 (USD MILLION) IN 2016, NORTH AMERICA IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE RESPIRATORY DIAGNOSTICS MARKET FOR TUBERCULOSIS.

  • Diagnostics
  • Hospital
  • Respiratory Disease
  • Market Size
  • Alere Inc.
  • Clinical Trial
  • Pharmaceutical
  • Pulmonary Delivery
  • Respiratory Disease
  • GlobalData's company
  • Clinical Trial
  • Respiratory Disease
  • United States
  • Company Financials
  • GlobalData's company

Phase II data and orphan drug designation from FDA and EMA for non tuberculosis mycobacterium is expected in ##H 2017.

  • Respiratory Disease
  • United States
  • World
  • Product Initiative
  • Cempra, Inc.

Bronchiectasis Global Clinical Trials Review, H##, 2016 Reference Code: GDHC##CTIDB Publication Date: DEC 2016 LIST OF TABLES LIST OF FIGURES Bronchiectasis Global Clinical Trials Review, H##, 2016 outlines clinical trials in Bronchiectasis.

  • Pharmaceutical
  • Respiratory Disease
  • World
  • Product Initiative
  • Pulmaquin group

These proteins are used for the treatment of various diseases such as asthma and COPD, diabetes, angina pectoris, cancer, bone disorders, migraine, and tuberculosis.

  • Respiratory Disease
  • Asia
  • World
  • Market Size
  • AstraZeneca PLC
  • CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) - PIPELINE BY MICROBION CORP, H1 2017
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2017 (CONTD..9), H1 2017
  • Respiratory Disease
  • Respiratory Treatment
  • United States
  • Product Initiative
  • AstraZeneca PLC

Nasacort Allergy ##HRTM should not be used when allergic to any of its ingredients, and in patients with active or dormant tuberculosis, or untreated fungal, bacterial and viral infection.

  • Allergy Drug
  • Pharmaceutical
  • Respiratory Disease
  • Therapy
  • Pfizer Inc.

The drug candidate is in Phase III stage of development for the treatment of bronchiolitis and in Phase II for chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and non tuberculosis mycobacterium in CF patients.

  • Respiratory Disease
  • United States
  • World
  • Product Initiative
  • Cempra, Inc.
  • Clinical Trial
  • Respiratory Disease
  • Therapy
  • United States
  • GlobalData's company
  • ALPHA-1 PROTEINASE INHIBITOR (HUMAN) SECOND GENERATION - DRUG PROFILE

Griffith is the Chief of the Medical Staff at the Texas Center for Infectious Disease (TCID) at San Antonio, Texas, and the Assistant Medical Director for the Heartland National Tuberculosis Center, which is also based at TCID in San Antonio, TX.

  • Respiratory Disease
  • Therapy
  • United States
  • Product Initiative
  • Pulmaquin group

Griffith is the Chief of the Medical Staff at the Texas Center for Infectious Disease (TCID) at San Antonio, Texas, and the Assistant Medical Director for the Heartland National Tuberculosis Center, which is also based at TCID in San Antonio, TX.

  • Respiratory Disease
  • Therapy
  • United States
  • Product Initiative
  • Pulmaquin group
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Tuberculosis A Randomized Controlled Trial of Moxifloxacin Versus Amoxicillin Clavulanate in the Treatment of Communityacquired Pneumonia and Infective Exacerbation of Bronchiectasis: Do Fluoroquinolones Delay the Diagnosis of Active Tuberculosis GDCT## HKCTR-##, L/ M No.

  • Anti-Infective
  • Clinical Trial
  • Pharmaceutical
  • Respiratory Disease
  • Aradigm Corporation
  • Clinical Trial Profile Snapshots

Tuberculosis Continuous Positive Airway Pressure on Tuberculosis Pleural Effusion GDCT## NCT##, Oliveira-## Respiratory Pleural Effusion, Tuberculosis Completed Phase II Interventional isoniazid; pyrazinamide; rifampin Federal University of Rio de Janeiro ## Mar

  • Lung Cancer
  • Respiratory Disease
  • Therapy
  • World
  • Product Initiative